Donepezil, Galantamine, Rivastigmine and Memantine for Alzheimer’s (review of R111)

Award Number
Award Type
Technology Assessment Reviews
Status / Stage
12 January 2010 -
25 November 2010
Duration (calculated)
00 years 10 months
Funding Amount
Funder/Grant study page
Contracted Centre
University of Exeter
Principal Investigator
Dr Mary Bond
WHO Catergories
Economic Impact of Dementia
Methodologies and approaches for risk reduction research
Disease Type
Alzheimer's Disease (AD)

CPEC Review Info
Reference ID163
ResearcherReside Team


Award Number09/87/01
Status / StageCompleted
Start Date20100112
End Date20101125
Duration (calculated) 00 years 10 months
Funder/Grant study pageNIHR
Contracted CentreUniversity of Exeter
Funding Amount£0.00


Management of Alzheimer’s disease involves treatment of cognitive, behavioural and psychological symptoms. Non-pharmacological treatment is social support and increasing assistance with day-to-day activities. These include: information and education, carer support groups, community dementia teams; home nursing and personal care, community services such as meals-on-wheels, befriending services, day centres, respite care and care homes. The HTA Programme commissioned this tehcnology assessment report on behalf of the National Institute for Health and Clinical Excellence.

Plain English Summary

This project will review and update the evidence presented to the National Institute of Health and Clinical Excellence in 2004 of how good a number of drugs (donepezil, galantamine, rivastigmine and memantine) are for treating Alzheimer’s disease. The assessment will also assess whether the reviewed drugs are likely to be considered good value for money for the NHS.